Search
Menu
Home
HTB
2020
December
HTB
December 2020
Contents
Editorial
HTB: no. 13/14 – HIV and COVID-19: issue 10 (9 December 2020)
i-Base appeal: please support i-Base with £5 or £10 a month
Conference reports
BHIVA 2020 virtual conference
Worryingly low HIV knowledge among health workers at London hospital: 80% unaware of U=U, 36% worried about their risk from patients
12th International Workshop on HIV paediatrics
Dolutegravir dosing for infants and young children
Antiretrovirals
EU approves dolutegravir 5 mg dispersible for children older than four weeks
New formulation of dolutegravir will make modern ART available for babies and young children at less than $120 a year
HIV prevention and transmission
Innovation benefits of cabotegravir LA injections for HIV PrEP will enable a closer FDA review
Once-monthly oral pill as PrEP against HIV: islatravir study to start in 2021
Resistance
High rates of drug resistance and virological failure among adults with HIV admitted to hospital in Malawi
Other news
World AIDS Day 2020: selected events
COVID-19: HIV and COVID-19 coinfection
Recent studies on HIV and COVID-19 coinfection
BHIVA statement on HIV positive people and access to COVID vaccines
COVID-19: vaccine
Early safety and immune responses in older people using the Oxford vaccine: overall results complicated by dosing error
Interim results report 94% efficacy with Moderna/NIH mRNA vaccine: FDA hearing on 17 December
HIV risk from some COVID-19 vaccines might be unlikely due to rarity of vector viruses involved
COVID-19: investigational drugs
Hydroxychloroquine fails to prevent COVID-19 or SARS-CoV-2 transmission when used as PEP
Hydroxychloroquine has no benefit on symptoms at 14 days
WHO SOLIDARITY study published in NEJM
International COVID-19 study launches in Africa but with drugs that have little chance of working (ANTICOV)
COVID-19: complications
Serious complications commonly reported three months after recovery from COVID-19
PDFs
HTB no 13–14 – plus: HIV and COVID-19 bulletin no 10 (9 December 2020)